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Abstract
Pulmonary hypertension (PHTN) is a rare and devastating disease characterized by progressive increases in pulmonary arterial 
pressure and pulmonary vascular resistance, which eventually leads to right ventricular failure and death. At present there is no 
cure for pulmonary arterial hypertension (PAH); however over the past decade targeted pharmaceutical options have become 
available for the treatment of PAH. Prior to evaluation for therapeutic options a definitive diagnosis of pulmonary arterial hyper-
tension must be made via comprehensive physical exam and definitive diagnostic testing. Screening test of choice remains 
echocardiography and gold standard for definitive diagnosis is right heart catheterization. Once the establishment of a diagnosis 
of PAH is made therapeutic options may be a possibility based on a diagnostic algorithm and disease severity of the PAH patient. 
There are different classes of medications available with different mechanisms of actions which have a vasodilatory effect and 
improve exercise tolerance, quality of life as well as survival. 
Key words: pulmonary arterial hypertension, phosphodiesterase type 5 inhibitors, endothelin receptor antagonist, prostacyclin 
analogues, right heart catheterization
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Introduction
Pulmonary hypertension (PHTN) is a rare and 
devastating disease characterized by progressive 
increases in pulmonary arterial pressure and pul-
monary vascular resistance which eventually leads 
to right ventricular failure and death [1]. Sympto-
matically it is characterized by increasing short-
ness of breath and worsening exercise tolerance. 
It may due to various etiologies such as left heart 
disease, parenchymal lung disease, chronic throm-
boembolic disease, hematologic disorders or it may 
be idiopathic in nature though the clinical picture 
of these patients is similar [2]. More specifically 
pulmonary arterial hypertension (PAH) is due to 
direct injury to the pulmonary vessels and vascular 
bed. At present there is no cure for PAH, however 
over the past decade targeted pharmaceutical 
options have become available for the treatment 
of PAH. There are different classes of medications 
available with different mechanisms of actions all 
which net a vasodilatory and anti-proliferative 
effect. These medications provide improvement in 
exercise tolerance, pulmonary hemodynamics and 
quality of life. This review will attempt to outline 
all the current treatment options for subject with 
PAH including new drugs that are on the horizon 
as based on newly published European Respiratory 
Society (ERS) and European Society of Cardiology 
(ESC) guidelines on the diagnosis and treatment 
of pulmonary hypertension [3].
Classification and diagnosis
Pulmonary hypertension (PHTN) is defined 
hemodynamically as a mean resting pulmonary 
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Table 1. World Health Organization’s Classification of Pulmonary Hypertension — Nice [modified from 2]
Group I — Pulmonary arterial hypertension 
 Idiopathic PAH
 Heritable (BMPR2, ALK1, Endoglin, Unknown)
   Familial disorder 
 Related conditions 
  Collagen vascular disease (Scleroderma)
  Congenital systemic-to-pulmonary shunt 
  Portal hypertension 
  Human immunodeficiency virus infection 
  Schistosomiasis
  Drugs and toxins (Aminorex ,Fenfluramine ,Dexfenfluramine) 
   Pulmonary veno-occlusive disease
 Persistent pulmonary hypertension of the newborn 
Group II — Pulmonary venous hypertension 
 Systolic dysfunction
 Diastolic dysfunction
 Valvular disease
Group III — Pulmonary hypertension associated with disorders of the respiratory system and/or hypoxemia 
 Chronic obstructive pulmonary disease 
 Interstitial lung disease 
 Sleep-disordered breathing 
 Alveolar hypoventilation disorders 
 Chronic exposure to high altitudes 
 Neonatal lung disease 
Group IV — Pulmonary hypertension resulting from chronic thrombotic and/or embolic disease (CTEPH) 
Group V — Pulmonary hypertension with unclear multifactorial mechanisms 
 Hematologic diseases: myeloproliferative disease, splenectomy
 Systemic diseases: sarcoidosis, Langerhans cell histiocytosis: neurofibromatosis, vasculitis
 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid diseases
artery pressure (mPAP) greater than or equal 25 
mm Hg. The World Health Organization (WHO) 
has proposed a classification system for pulmo-
nary hypertension based on common clinical 
features and etiology which has been outlined 
in Table 1 [2]. Pre-capillary pulmonary hyper-
tension which encompasses pulmonary arterial 
hypertension (PAH) (WHO Group I), PHTN due to 
primary lung disease (WHO Group III), Chronic 
Thromboembolic PHTN (WHO Group IV) and 
PHTN with an unclear or multifactorial etiology 
(WHO Group V), is defined as a mPAP greater 
than or equally to 25 mm Hg as well as a pulmo-
nary artery wedge pressure (PAWP) less than or 
equal to 15 mm Hg which must be confirmed by 
right heart catheterization (RHC) [3]. Pulmonary 
vascular resistance (PVR) has also been added to 
the definition of PAH. Definitions of PHTN, PAH 
and subgroups of PHTN have been outlined in 
Table 2 [3]. 
Pharmacological management
Once the establishment of a diagnosis of 
PAH is confirmed via RHC, therapeutic options 
may be a possibility based on an algorithm (Fig. 
1) and PAH disease risk stratification outlines in 
Table 3. In PAH, the pulmonary vasculature is 
the exclusive target of disease. The pathologic 
vasoconstriction and inflammatory vascular re-
modeling associated with PAH is a prominent fe-
ature leading to the rationale for using pulmonary 
vasodilators therapies and now options are many. 
The pathophysiology of PAH lies within endothe-
lial dysfunction which leads to an imbalance of 
vasodilator and vasoconstrictor mediators ulti-
mately resulting in vasoconstriction. In addition 
dysfunction of the endothelium leads to release 
of pro-inflammatory mediators. The elucidation 
of molecules involved in the regulation of pul-
monary vasculature has led to the development 
of currently approved PAH therapies, which all 
target one of the following key pathways: (1) 
prostacyclin (PGI2), (2) nitric oxide (NO), and (3) 
endothelin-1 (ET-1) pathways shown in Figure 2. 
Treatment goals in the setting of PAH are 
focused on the improvement of both hemodyna-
mic parameters and exercise tolerance, resulting 
in increased survival. Commonly evaluated 
parameters include: WHO functional class (FC), 
hemodynamic parameters, mainly right atrial 
pressure, cardiac index and mixed venous oxy-
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Table 2. Hemodynamic definitions of pulmonary hypertension [3]
Definition Hemodynamics Clinical Subgroup
Pulmonary Hypertension (PHTN) mPAP ≥ 25 mm Hg All types of PHTN
Pre-capillary PHTN mPAP ≥ 25 mm Hg
PCWP ≤ 15 mm Hg
WHO Group I — Pulmonary arterial hypertension
WHO Group III — PHTN due to lung disease
WHO Group IV — Chronic thromboembolic PHTN
WHO Group V — PHTN due to unclear and/or multifacto-
rial etiology
Post-capillary PHTN
Isolated post-capillary PHTN
Combined post-capillary and pre-
capillary PHTN
mPAP ≥ 25 mm Hg
PCWP > 15 mm Hg
DPG < 7 mm Hg and/or PVR ≤ 3 WU
DPG ≥ 7 mm Hg and/or
PVR > 3 WU
WHO Group II — PHTN due to left heart disease
WHO Group V — PHTN due to unclear and/ 
/or multifactorial etiology
mPAP — mean pulmonary arterial pressure; PCWP — pulmonary capillary wedge pressure; DPG — diastolic pressure gradient (diastolic PAP — mean PCWP); PVR 
— pulmonary vascular resistance; WU — wood units
Figure 1. Treatment algorithm for pulmonary arterial hypertension patients; CCG — calcium channel blockers
gen saturation, right atrial area and pericardial 
effusion presence on echocardiography, distance 
covered on 6 minute walk test (6MWT), peak VO2 
on cardiopulmonary exercise testing and B-type 
natriuretic peptide (BNP) levels. Goals of PAH 
therapy have been outlined in Table 4 [4].
The following section will serve to outline 
general measures and pharmaceutical options 
that exist in the treatment of PAH. The Europe-
an Respiratory Society has put forth Classes of 
Recommendation as well as Levels of Evidence 
to determine what therapies are most efficacious 
based on evidence in the literature which have 
been reflected in the presented tables [3]. Clas-
ses of recommendations are as follows: Class I: 
Evidence and/or general agreement that a given 
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Table 3. Risk Stratification of PAH Patients based on ERS Guidelines [3]
Clinical Determinant Low Risk Intermediate Risk High Risk
Clinical signs of right heart failure No No Yes
Symptom progression No Gradual Rapid
Syncope No Occasional Repeated
WHO functional class I, II III IV
6MWD > 440 m 165−440 m < 165 m
NT-proBNP Plasma levels BNP < 50 ng/l
NT-proBNP < 300 ng/ml
BNP 50−300 ng/l
BT-proBNP 300−1400 ng/l
BNP > 300 ng/l
BT-proBNP > 1400 ng/l
CPET peak VO2 Peak VO2 > 15 ml/min/kg Peak VO2 11−15 ml/min/kg Peak VO2 < 1 ml/min/kg
Echocardiography Findings RA are < 18 cm2
No pericardial effusion
RA area 18−26 cm2
No or minimal pericardial effusion
RA are > 26 cm2 Pericar-
dial effusion
Hemodynamics RAP < 8 mm Hg
CI ≥ 2.5 l/min/m2
RAP 8−14 mm Hg
CI 2.0−2.4 l/min/m2
RAP > 14 mm Hg
CI < 2.0 l/min/m2
6MWD — 6-minute walk distance; BNP — brain natriuretic peptide; CI — cardiac index; NT-proBNP – n-terminal brain natriuretic peptide; RA — right atrium; RAP 
— right atrium pressure; VO2 — oxygen consumption
cAMP — cyclic adenosine monophosphate; cGMP — cyclic guanosine monophosphate; ET — endothelin receptor; GTP — guanosine triphosphate; PDE5 — cGMP
-specific phosphodiesterase type 5; PgI2 — prostacyclin; sGC — soluble guanylate cyclase
Figure 2. Mechanism of action and rationale of approved PAH therapies
treatment or procedure is beneficial, useful and 
effective; Class II: Conflicting evidence and/or 
a divergence of opinion about the given favor 
of usefulness/efficacy of the given treatment or 
procedure: Class IIa: Weight of evidence/opinion 
is in favor of usefulness/efficacy; Class IIb: Useful-
ness/efficacy is less well established by evidence/
opinion; Class III: Evidence or general agreement 
that the given treatment or procedure is not use-
ful/effective, and in some cases may be harmful. 
Levels of evidence are as follows: Level of evi-
dence A: Data derived from multiple randomized 
clinical trials or meta-analysis; Level of evidence 
B: Data derived from a single randomized trial or 
large non-randomized studies; Level of evidence 
C: Consensus of opinion of the experts and/ or 
small studies, retrospective studies, registries [3].
General measures and non-specific therapies 
General measures can be applied to all pa-
tients found to have PAH; Recommendations set 
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Table 4. Goals of PAH specific therapy (adapted from [4])
Functional class I or II 
Echocardiography/cardiac magnetic resonance normal/near normal RV size and function 
Hemodynamics RAP, 8 mm Hg; CI 2.5 to 3.0 L/min/m2 
6-min walk distance > 330 to 440 meters may not be aggressive enough in young 
individuals 
Cardiopulmonary exercise testing Peak VO2 > 15 ml/min/kg ; EQCO2 <45 l/min/l/min 
B-type natriuretic peptide level normal 
CI — cardiac index; RAP — right atrial pressure; RV — right ventricle
Table 5. Recommendations for General Measures [3]
Recommendations Class Level
Pregnancy is contraindicated in PAH I C
PAH patients should be immunized against influenza and pneumococcal infection I C
Psychosocial support is recommended in PAH patients I C
Supervised exercise training should be considered in PAH therapy under medical therapy IIa B
In elective surgery, epidural rather than general anesthesia should be used IIa C
Excessive physical activity that leads to distressing symptoms should be avoided in PAH patients III C
Table 6. Recommendations for Supportive Pharmacotherapy [3]
Recommendations Class Level
Continuous long term oxygen therapy is recommended in PAH patients when oxygen press is less than 60 mm Hg I C
Diuretic treatment in PAH patients with evidence of right ventricular failure and fluid retention I C
Oral anticoagulant use in patients with idiopathic or heritable PAH and PAH due to anorexigen use IIb C
Correction of anemia and/or iron status in PAH patients IIb C
forth by the ERS have been outlined in Table 
5. In addition to above-mentioned supportive 
measures, some pharmacotherapy may be used 
in conjunction with PAH specific therapies. 
Continuous long-term oxygen therapy should be 
initiated in patients who are not able to maintain 
adequate oxygen saturation (PaO2 less than 60 
mm Hg) [5]. In general patients found to have 
PAH should adhere to a low sodium diet to avoid 
volume overload and the careful use of diuretics 
can be helpful in reducing volume and right heart 
strain [6]. Care should be taken to avoid excessive 
diuresis to avoid reduction of cardiac output. It 
has also been suggested that PAH patients are at 
risk for in situ thrombosis of altered pulmonary 
vessels which may contribute to disease progres-
sion and it has been proposed that therapeutic 
anticoagulation might have beneficial effects 
[7]. Recently concluded COMPERA registry has 
provided further proof of survival advantage for 
patients with idiopathic PAH, heritable PAH and 
drug induced PAH treated with anticoagulants, 
suggesting that these patients benefit from the-
rapeutic anticoagulation. The situation remains 
inconclusive for patients with other forms of PAH 
for whom no therapeutic effect of anticoagula-
tion was detectable [8]. In addition a study has 
shown that correction of anemia or optimization 
of iron status may be beneficial in the setting of 
PAH [9]. Recommendations for the use of support 
pharmacotherapy has been shown in Table 6. 
After general measures are initiated PAH speci-
fic therapies may be initiated which have been 
described below.
Calcium channel blockers
For a select group of pulmonary hypertension 
patients, which include only idiopathic PAH, he-
ritable PAH or drug-induced PAH patients, high 
dose calcium channel blocker (CCB) therapy may 
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be an option. To determine if CCBs are a viable 
option for such patients, pulmonary vasoreacti-
vity testing for identification of patients is recom-
mended at time of RHC [3]. Acute vasoreactivity 
is performed with the use of inhaled nitric oxide 
(NO) at 10–20 parts per million (ppm) but i.v. epo-
prostenol, i.v. adenosine or inhaled iloprost can 
be used as alternatives. A positive acute response 
is defined as a reduction of the mean PAP ≥ 10 
mm Hg to reach an absolute value of mean PAP 
≤ 40 mm Hg with an increased or unchanged CO. 
Only about 10% of patients with idiopathic PAH 
will meet these criteria [10, 11]. In patients who 
show evidence of an acute hemodynamic respon-
se to selective vasodilators during RHC, long-term 
treatment with CBB, administered orally in high 
dosages, can produce a sustained hemodynamic 
response and increase survival [12]. Comparison 
of responders to acute vasoreactivity testing with 
the remaining PAH patients revealed that they 
had less severe disease at baseline. During acute 
vasodilator testing, long-term CCB responders 
displayed a more pronounced fall in mean PAP 
and after 7.0 ± 4.1 years, all but 1 long-term CCB 
responders were alive in NYHA class I or II, with 
a sustained hemodynamic improvement. In the 
group of patients who failed on CCB, the 5-year 
survival rate was 48% [10]. 
Prostacyclin analogues
Released by the endothelial cells’ prostacyc-
lin I2 (PGI2) is a potent pulmonary vasodilator, 
exerting its effects via adenylate cyclase. The 
other mechanisms of action are: the inhibition 
of platelet aggregation and anti-proliferative 
effect. Epoprostenol is a PGI2 derivative which 
has been shown to improve exercise capacity, 
Table 7. Recommendations on the use of Prostacyclin Analogues (adapted from Galie at al. [3])
Treatment Class and Level of Recommendation References
WHO FC II WHO FC III WHO FC IV
Epoprostenol Intravenous – – I A I A [14, 15]
Iloprost Inhaled – – I B IIB C [21]
Intravenous* – – IIa C IIB C [60]
Treprostinil Subcutaneous – – I B IIB C [17]
Inhaled* – – I B IIB C [18]
Intravenous – – IIa C IIB C [19]
Oral* – – II B – – [20]
Beraprost* – – IIb B – – [61]
*Not approved by European Medicine Agency (EMA) at time of ERS Guidelines publication [3]
quality of life, hemodynamics and long-term 
survival in PAH patients [13, 14]. Demonstrative 
trial of epoprostenol showed that patient with 
PAH classified as NYHA functional class III or IV 
were randomized to receive either conventional 
therapy alone (warfarin, diuretics, oxygen, and 
oral vasodilators) or conventional therapy and 
epoprostenol. Patients in the epoprostenol group 
had functional improvement, 6MWD (362 m at 
12 weeks vs. 315 m at base line) and a decrease 
in mPAP and pulmonary vascular resistance [15]. 
There exists also a thermostable form of epopro-
stenol that lessens its burden of use and may 
improve patient compliance [16].
Treprostinil is a prostacyclin analogue that 
has also been successful in treating PAH by 
improving exercise capacity, functional class, 
hemodynamics and quality of life [17]. It exists 
in injectable form as well as a continuous sub-
cutaneous infusion. A double-blind, placebo-
controlled multicenter trial in PAH showed that 
exercise tolerance improved (median change of 
+10 m (−24 to 47 m; 25th–75th percentile) while 
unchanged in the placebo (median change of 0 
m (−44 to 32 m; 25th–75th percentile). It was also 
seen that, treprostinil significantly improved 
indices of dyspnea, signs and symptoms of pul-
monary hypertension, and hemodynamics [17]. 
Of note is the fact that there may be site pain at 
insertion of subcutaneous catheter. Inhaled [18] 
and intravenous [19] treprostinil are also options 
for class II and IV patients. More recently an oral 
form of treprostinil has been approved as a first 
line therapy for patients exhibiting functional 
class III symptoms [20]. 
Inhaled iloprost has also been shown to in-
duce vasodilatation lasting up to 60−120 minu-
tes and has been shown to improve the dyspnea 
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scores and hemodynamic variables but the major 
limitation was the repetitive inhalation 6−9 times 
daily [21]. A randomized, multicenter, placebo-
controlled trial involving patients from WHO 
function class III or IV with PAH used as a com-
bined end point a 10 percent increase in patients’ 
scores on a six-minute walk test and improvement 
in NYHA functional class [21]. Seventeen percent 
of treated patients reached this end point, as com-
pared with 4 percent of the placebo group. There 
was a gain of 59 m on 6MWD among patients with 
PAH. Side effects included cough and symptoms 
linked to systemic vasodilatation. In addition, 
syncope was more frequent in the iloprost group 
than in the placebo group. Recommendations 
have been presented in Table 8.
Endothelin pathway (endothelin receptor 
antagonists (ERA))
Endothelin1 (ET-1) is a potent vasoconstrictor 
and increased levels of ET-1 in vascular endothe-
lial cells and in plasma has been demonstrated in 
patients with PAH which serves as the rationale 
for the ERAs. Bosentan was the first ERA approved 
by the Food and Drug Administration (FDA) for 
the management of PAH for use in patients with 
PAH associated with FC II–IV symptoms [22, 23]. 
Initial studies on WHO Functional Class III scle-
roderma related PAH patients showed that in the 
bosentan group 6MWD and cardiac index signi-
ficantly improved and that pulmonary vascular 
pulmonary vascular resistance decreased. Patients 
given bosentan also experienced a reduction of 
Borg dyspnea index and an improved WHO func-
tional class [24]. Efficacy was further confirmed 
by the subsequent BREATHE-1 (Bosentan Rando-
mized Trial of Endothelin Antagonist Therapy) 
trial [17] in which PAH patients who were NYHA 
functional classes III and IV showed improvement 
in WHO functional class and the prolongation of 
time to clinical worsening. Increases in liver ami-
notransferases greater than 8 times the upper limit 
of normal were again noted in the bosentan group 
and were dosage-dependent: with 2 patients in 
the 125-mg group and 5 patients in the 250-mg 
group [17]. Bosentan was also studied in NYHA 
functional class II patients and has demonstrated 
positive outcomes in this group of patients [23]. 
Ambrisentan is a highly selective ET-A an-
tagonist with a long half-life to allow once daily 
dosing that has been approved for PAH functio-
nal classes II and III. Data from two studies have 
shown that ambrisentan taken over 12 weeks 
significantly improved 6MWD in PAH patients. 
Associated extension study data also confirmed 
that continuation of treatment for two years 
was associated with sustained improvements in 
exercise capacity and a reduced risk of clinical 
worsening and death [25]. After demonstrating a 
favorable safety and efficacy profile in an initial 
dosing study [26] showing improvement in pul-
monary hemodynamics two randomized contro-
lled trials, ARIES-1 and ARIES-2 (ARIES-1, 5 mg, 
10 mg, placebo; ARIES-2, 2.5 mg, 5 mg, placebo) 
were conducted [27]. Both trials showed impro-
vement in 6MWD and in the ARIES-2 trial, there 
was a significant improvement in time to clinical 
worsening. Improvement in WHO functional class 
was found to be significant in the ARIES-1 trial 
and it was observed in the ARIES-2 trial, but again 
it was not found to be statistically significant. 
Macitentan is the newest Food and Drug 
Administration (FDA) approved tissue-targeting 
ERA that has been shown to significantly decrease 
the risk of a morbidity and mortality event over 
the treatment period, and improved 6MWD and 
NYHA FC [28]. Macitentan is a tissue targeting 
endothelin receptor blocker that inhibits binding 
of ET-1 to receptors ET-A and ET-B that has been 
FDA approved for NYHA Class II-III pulmonary 
arterial hypertension. Macitentan is a lipophi-
lic sulfamide compound designed to decrease 
vascular resistance by exhibiting enhanced tissue 
penetration and prolonged receptor binding to 
ET-A/ET-B in pulmonary arterial smooth muscle 
cells [29]. 
A long term randomized, controlled study 
(SERAPHIN) was conducted. The study was 
intended to determine safety and efficacy of 
Table 8. Recommendations on the use of Endothelin Receptor Antagonists (adapted from Galie at al. [3])
Treatment Class and Level of Recommendation References
WHO FC II WHO FC III WHO FC IV
Ambrisentan I A I A IIb C [25−27]
Bosentan I A I A IIb C [17, 22−24, 42]
Macitentan I B I B IIb C [30]
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macitentan until the first sign of clinical wor-
sening and all-cause mortality in patients with 
symptomatic pulmonary arterial hypertension. 
Patients were on Macitentan therapy up to 42 
months and a total of 250 patients were randomly 
assigned to placebo, 250 patients to macitentan 
3 mg once-daily, and 242 to macitentan 10 mg 
daily. Macitentan, at both the 3 mg and 10 mg 
doses met primary endpoints, decreasing the risk 
of a morbidity/mortality over the treatment period 
versus placebo [30]. 
This risk was found to be reduced by 45% 
in the 10 mg dose group (p < 0.0001) and the 
3 mg group showed a risk reduction of 30% (p 
= 0.01). Secondary endpoints included 6MWD 
change in the first 6 months of therapy as well as 
NYHA functional class and time to either death 
or hospitalization due to PAH. These endpoints 
also showed a dose dependent effect (p < 0.05 
for either dose) [30]. 
Adverse events and discontinuation of treat-
ment due to adverse events was similar across all 
groups. Adverse events associated with maciten-
tan were headache, nasopharyngitis, and anemia. 
Elevations of liver aminotransferases greater 
than three times the upper limit of normal were 
observed in 4.5% of patients receiving placebo, 
in 3.6% of patients on 3 mg of macitentan and in 
3.4% of patients on 10 mg of macitentan [30]. Re-
commendations have been presented in Table 8.
Nitric Oxide Pathway (Phosphodiesterase 5 
Inhibitors)
Nitric Oxide (NO) is a short acting endogeno-
us molecule that plays a key role for controlling 
vascular smooth muscle tone that results in vaso-
dilatation and inhibiting proliferation. NO diffu-
ses through cells and activates soluble guanylate 
cyclase leading to an increase in cyclic guanosine 
3’−5’ monophosphate (cGMP) resulting in smooth 
muscle relaxation. The enzyme PDE-5 inhibitors 
are abundantly expressed in high concentration in 
the lungs, platelets and vascular smooth muscle 
and are responsible for degradation of cGMP [31].
At the level of the endothelium nitric oxide 
indirectly acts as a potent vasodilator by upre-
gulating the production of cyclic guanosine mo-
nophosphate (cGMP). Phosphodiesterase type 5 
(PDE-5) is an enzyme that degrades cGMP leading 
to vasoconstriction [31]. Sildenafil, the first PDE-5 
inhibitor approved for PAH is indicated for pa-
tients with FC II-III symptoms. Patients that are 
on this medication have shown improvement in 
symptoms, 6MWD as well as FC [26]. Clinical 
research studies have found sildenafil to improve 
pulmonary hemodynamic and exercise capacity 
in PAH patients.
Initially a double blinded, placebo-control-
led, cross over study of 22 patients randomized 
to receive sildenafil or placebo for 6 weeks and 
then crossed over with a primary endpoint of 
exercise tolerance demonstrated clinical efficacy 
[32]. Patients on sildenafil showed significant 
improvement in exercise time while the placebo 
arm showed a decrease in exercise tolerance. 
Other improvements noted were cardiac index 
assessed by echocardiography along with dysp-
nea and fatigue components of QoL, however no 
significant improvement was seen in estimated 
pulmonary artery systolic pressure (PASP) [32]. 
The trial that demonstrated clinical efficacy 
of sildenafil was the SUPER-1 trial [33]. The SU-
PER-1 trial was a double blind, multi- center, pla-
cebo controlled study of 278 PAH patients. PAH 
symptomatology was either idiopathic, associated 
with connective tissue disease or with repaired 
congenital systemic to pulmonary shunts. Most 
patients belonged to WHO functional class II 
(39% of patients) or III (58% of patients). Patients 
were randomized to receive placebo or sildenafil 
20 mg, 40 mg or 80 mg three times daily for 12 
weeks. The primary endpoint of the study was to 
monitor for change in distance walked in 6 minu-
tes from baseline to 12 weeks. By the end of 12 
weeks, there was significant improvement in walk 
distance of 45 m, 46 m and 50 m in all three dose 
regimens of 20 mg, 40 mg and 80 mg, respectively. 
Sildenafil was found to improve exercise capacity 
in all three groups over placebo. The study also 
noted a significant improvement in hemodyna-
mic measurements such as mPAP, cardiac index 
and PVR. There was also improvement change 
in functional class, with no significant delay in 
time to clinical worsening or Borg Dyspnea Index 
(BDI) [33].
Tadalafil is the second PDE-5 inhibitor to be 
approved for PAH WHO Group 1 patients. The 
first large scale trial to study the efficacy of Tada-
lafil was the PHIRST study [34]. The study was a 
16 weeks double blinded, placebo controlled and 
multi-centered study of 405 patients (WHO Group 
1, FC II or III) who were either on bosentan or one 
of five treatment arms. Patients were randomized 
into once daily dosing of 2.5 mg, 10 mg, 20 mg, 
40 mg or a placebo group. The primary endpoint 
of study was to detect any change in 6MWD from 
baseline. Along with 6MWD, secondary endpoints 
measured were WHO FC, hemodynamic changes, 
Borg dyspnea scale and quality of life. It was fo-
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und the tadalafil group showed an improvement 
in 6MWD. There was also reduced incidence of 
clinical worsening, fewer hospitalizations and 
showed significant improvement, in health rela-
ted QoL, No improvement was observed in Borg 
dyspnea score or WHO classification for any given 
treatment arm, which was a consistent finding 
with other studies as well. Recommendations 
have been presented in Table 9. 
Soluble guanylate cyclase (sGC) 
stimulator 
Riociguat is a direct sGC stimulator that is 
the only therapy approved by the Food and Drug 
Administration. Riociguat stabilizes NO-soluble 
guanylate cyclase coupling and directly stimu-
lates soluble guanylate cyclase, increasing the 
production of cyclic guanosine monophosphate 
(cGMP) and causing vasodilation [35]. In addition 
it acts in synergy with NO to produce anti-aggre-
gatory, anti-proliferative and vasodilatory effects 
[36, 37] by increasing the concentrations of cGMP.
The PATENT-1 Trial was a phase 3, double 
blinded study that riociguat improved the 6-mi-
nute walk distance both in naïve patients and 
patents who were also on in those who were 
receiving ERAs or prostanoids (+30 m in the 
2.5 mg-maximum group and had decreased by a 
mean of 6 m in the placebo group (least-squares 
mean difference, 36 m; 95% confidence interval, 
20 to 52; P < 0.001). There were significant im-
provements in pulmonary vascular resistance, 
NT-proBNP levels, WHO functional class, time to 
clinical worsening, and Borg dyspnea score [38]. 
Generally riociguat is well tolerated with the most 
common side effects are headache and dizziness 
which has been seen in up to one quarter of pa-
tients. Other common side effects include upset 
stomach, leg swelling, runny nose and nausea. 
Syncope was only seen one percent of patients. It 
is important to note that riociguat is metabolized 
thought the cytochrome p450 pathway, most spe-
cifically CYP1A1. For these reason patients who 
smoke may require increased dosages due to fact 
that CYP1A1 is inducible by chemicals found in 
cigarette smoke [39]. In addition riociguat is the 
only drug that has been approved for the treat-
ment of WHO Group IV chronic thromboembolic 
pulmonary hypertension (CTEPH) [40]. For the 
treatment of WHO FC II and III, the ERS guideli-
nes give a IB Class-Level recommendation and for 
WHO FC IV patients a IIb-C recommendation [3].
Combination therapy 
With the presence of multiple pathways at 
play in the treat of PAH, the possibility to use 
a more than one medication exists. It is known 
that up to 36% of patients receive combinations 
therapy and up to 9% receive triple therapy [41]. 
Initially it was the BREATHE-2 study, a randomi-
zed controlled trial that evaluated initial combi-
nation which failed to demonstrate any significant 
advantage of initial combination of epoprostenol 
and bosentan compared with epoprostenol alone 
[42]. More recently though the AMBITION trial, 
in which initial therapy with tadalafil and ambri-
sentan was found to be superior to monotherapy 
and showed a 50% risk reduction in clinical 
worsening and well as increased 6MWD and PAH 
related hospitalizations [43]. However it is still 
unclear if upfront combination therapy improves 
long-term outcomes in comparison to sequential 
add-on therapy in case of poor response to mo-
notherapy. Recommendations have been outlined 
in Table 10. 
After initialization of PAH specific therapy 
patients are reassesses in 3−6 months. Certain 
parameters are taken into account to see if the 
patient is responding to initiated medication. 
Clinical response is based on patients overall 
feeling, WHO functional class, exercise capaci-
ty, estimated echocardiogram pressures, 6MWD 
amongst others. If clinical response is found to be 
inadequate then addition of a second or tertiary 
medication may be warranted. Meta-analysis of 
data shows that combination therapy is beneficial 
to patients [44]. Multiple studies have addressed 
add-on combination therapy such as the STEP 
Table 9. Recommendations on the use of Phosphodiesterase 5 Inhibitors (adapted from Galie at al. [3])
Treatment Class and Level of Recommendation References
WHO FC II WHO FC III WHO FC IV
Sildenafil I A I A IIb C [32, 33]
Tadalafil I B I B IIb C [34]
Vardenafil* IIb B IIb B IIb C [51]
*Not approved by European Medicine Agency (EMA) at time of ERS Guidelines publication [3]
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Table 10. Recommendations on the use Combination Therapy in PAH (adapted from Galie at al. [3])
Combination Therapy Class and Level of Recommendation References
WHO FC II WHO FC III WHO FC IV
Ambrisentan + tadalafil I B I B IIb C [43]
Other ERA + PDE-5i IIa C IIa C IIb C –
Bosentan + sildenafil + epoprostenol – – IIa C IIa C [62]
Bosentan + epoprostenol – – IIa C IIa C [63]
ERA — endothelin receptor antagonists; PDE-5i — phosphodiesterase 5 Inhibitors
Table 11. Recommendations on the use sequential Combination Therapy in PAH according to WHO FC (adapted from Galie 
at al. [3])
Combination Therapy Class and Level of Recommendation References
WHO FC II WHO FC III WHO FC IV
Macitentan added to sildenafil I B I B IIa C [30]
Riociguat added to bosentan I B I B IIa C [38]
Selexipag* added to ERA and/or PDE-5i I B I B IIa C [49, 50]
Sildenafil added to epoprostenol – – I B IIa B [64]
Inhaled treprostinil added to sildenafil or bosentan IIa B IIa B IIa C [18]
Inhaled iloprost added to bosentan IIb B IIb B IIb C [45]
Tadalafil added to bosentan IIa C IIa C IIa C [34]
Ambrisentan added to sildenafil IIb C IIb C IIb C [65]
Bosentan added to epoprostenol – – IIb C IIb C [66]
Bosentan added to sildenafil IIb C IIb C IIB C [67, 68]
Sildenafil added to bosentan IIb C IIb C IIb C [68]
Other double/triple combination IIb C IIb C IIb C –
Riociguat added to sildenafil or other PDE-5i III B III B III B [48]
*Not approved by European Medicine Agency (EMA) at time of ERS Guidelines publication [3]; ERA — endothelin receptor antagonist; PDE-5i — phosphodiesterase 
5 inhibitors
study in which inhaled iloprost was added to 
patients already on bosentan. Though a small 
sample size, results of this study demonstrate 
that the addition of inhaled iloprost in patients 
with PAH with reduced exercise capacity on bo-
sentan monotherapy is safe and efficacious (+26 
m on 6MWT) [45]. Similarly The TRIUMP I study 
showed that PAH patients who remain sympto-
matic on bosentan or sildenafil, the addition of 
inhaled treprostinil improves exercise capacity 
and quality of life and is safe and well-tolerated 
[18]. As for other trials, it has been seen that the 
addition of the ERA macitentan to pretreated 
patients significantly delayed PAH related events 
[30] and that addition of bosentan to sildenafil n 
the COMPASS-2 trial improved exercise capacity 
at week 16 but did not meet other primary end-
points [46]. The recommendations on efficacy of 
sequential combination therapy set worth by the 
ERS have been outlined in Table 11.
Drug interactions
With the majority of patient with severe PAH 
being placed on combination therapy and eviden-
ce pointing towards initial combination therapy, 
the use of multiple drugs working on multiple 
pathways creates the possibility of drug-drug inte-
ractions and should be considered by physicians 
when prescribing PAH specific therapy. 
Clinicians must take some considerations 
even in the setting of monotherapy. The PDE-
5 sildenafil is metabolized via the cytochrome 
P450 pathway specifically involving CYP3A4 and 
CYP2C9. There is an increase in sildenafil bioava-
ilability and reduced clearance with CYP3A4 
substrates and inhibitors and CYP3A4 substrates 
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Table 12. Potential Interactions Between Pulmonary Arterial Hypertension-specific Medications for Concurrent Illnesses
Statins      Sulph. RTIs Protease 
Inhibitors
Af Cyclos. Hormonal  
Contraceptives
Prostacyclin Analogues
Epoprostenol – – – – – – –
Treprostinil – – – – – – –
Iloprost – – – – – – –
Phosphodiesterase Type 5 
Inhibitors
Sildenafil – X – X X – –
Tadalafil – X – X X – –
Soluble Guanylate Cyclase 
Stimulators
Riociguat X X – X X X –
Endothelin Receptor Anta-
gonists
Bosentan X X X X X X X
Ambrisentan – – – X – X –
Macitentan – – – X – X –
All data was obtained from FDA Drug Information Data; RTI — reverse transcriptase inhibitor; X — known interaction; – — no known interaction or not clinically 
significant interaction; Cyclos — cyclosporine A; Barb — barbituates; Af — antifungals
plus beta-adrenoceptor blockers. Drugs that are 
CYP3A4 inducers such as barbiturates, rifampicin 
and St John’s wort may lower sildenafil levels and 
should be used with caution. Sildenafil levels are 
modestly increased by fresh grapefruit juice, a 
weak inhibitor of CYP3A4 [3].
The ERA bosentan is an inducer of cyto-
chrome P450 isoenzymes CYP3A4 and CYP2C9. 
Plasma concentrations of drugs metabolized by 
these isoenzymes will be reduced when co-ad-
ministered with bosentan. Of note is that the 
combination of a potent CYP3A4 inhibitor (ke-
toconazole, ritonavir) and/or a CYP2C9 inhibitor 
(e.g. amiodarone, fluconazole) with bosentan may 
cause a significant increase in plasma bosentan 
levels and thus is contraindicated. Interactions 
may theoretically occur with certain antifungals 
as well as immunosuppressive drugs. An outline 
of PAH specific medications and interactions with 
commonly used drugs is shown in Table 12.
Now with PAH specific combination therapy 
becoming commonplace there are a few important 
therapeutic combinations that should be avoided. 
The use of ERA bosentan with PDE-5 sildenafil 
has been shown to significantly decrease plasma 
concentrations of sildenafil [47]. In addition the 
PATENT PLUS trial studied the effect of adding 
the soluble guanylate cyclase stimulator, riociguat 
to background sildenafil therapy which concluded 
that riociguat in combination with sildenafil was 
associated with high rates of discontinuation due 
to hypotension, SAEs and deaths [48]. Therefore 
concomitant use of riociguat with PDE-5 inhibi-
tors (such as sildenafil, tadalafil and vardenafil) is 
contraindicated. Common dosing of medications 
has been presented in Table 13.
Future medications
As the vascular wall remain the primary 
target in PAH specific drugs, new medications 
focus on these biological pathways. The majority 
of current therapeutic research is focused on the 
prostacyclin and nitric oxide pathways. Selexipag 
is an oral, selective prostacyclin receptor agonist 
which is currently awaiting approval of the FDA. 
In a proof of concept study by Simonneau et al. 
it has been found that Selexipag use in patients 
already receiving ERA or PDE-5 therapy, resulted 
in a 30.3% reduction in mean pulmonary vascular 
resistance versus placebo and systemic vascular 
resistance along with an increase in cardiac index 
[49]. The formal results of the GRIPHON study, 
a multicenter, double blinded, placebo control-
led phase 3 study of 1156 show that selexipag 
reduced the risk of mortality/morbidity events 
vs. placebo by 40% and the treatment effect was 
consistent across age, gender, etiology, baseline 
FC and background PAH therapy sub-groups [50]. 
Though not yet approved by the EMA based on 
the ERS guidelines a Class-Level recommendation 
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Table 13. Pulmonary Arterial Hypertension Medications Dosing
Medication Class and typical drug dosing range Adverse Effects 
Phosphodiesterase Type-5 Inhibitors
Sildenafil
Oral: 5mg or 20 mg three times daily; separate dosing by 4–6 hrs
IV: 2.5-mg or 10-mg bolus three times daily 
Epistaxis, headache, dyspepsia, flushing, insomnia, erythema, 
dyspnea worsened, rhinitis, sinusitis, myalgia, pyrexia, paresthesia; 
hypotension, vision or hearing loss, priapism, vaso-occlusive crisis
Tadalafil
40 mg once daily. CrCl 31–80 ml/min: initially 20mg once daily, 
increase to 40 mg once daily if tolerated. CrCl < 30 ml/min: not 
recommended 
Headache, myalgia, nasopharyngitis, flushing, respiratory tract 
infection, pain, nausea, dyspepsia, sinus congestion; hypotension, 
sudden vision or hearing loss, priapism, prolonged erection
Soluble Guanylate Cyclase (sGC) Stimulator
Riociguat
0.5−2.5 mg daily in three divided
Hypotension (low blood pressure), headache, and gastrointestinal 
disorders 
Endothelin Receptor Antagonists 
Ambrisentan
5−10 mg daily
Peripheral edema, nasal congestion, sinusitis, flushing, elevated liver 
enzymes; decreased sperm counts, hematologic changes
Bosentan
< 40 kg: 62.5 mg twice daily. > 40 kg: Initially 62.5 mg twice daily 
for 4 weeks, then 125 mg twice daily. Take in the AM and PM
Hepatotoxicity, respiratory tract infection, headache, edema, chest 
pain, syncope, flushing, hypotension, sinusitis, arthralgia, elevated 
liver enzymes, palpitations, anemia; decreased sperm counts
Macitentan
10 mg once daily
Hepatotoxicity, Anemia, lightheadedness, headache, urinary tract 
infection
Prostacyclin Analogues 
Treprostinil
IV/SQ: 1−10 mg/ml for infusion. 
Oral − 0.125 mg, 0.25 mg, 1 mg, 2.5 mg twice daily, titrating up.
Inhaled − 1.74 mg in 2.9 ml inhalation. 3 breaths of treprostinil per 
treatment session, 4 times daily
Infusion reactions/site pain, headache, diarrhea, nausea, jaw pain, 
vasodilatation, dizziness, edema, pruritus, hypotension
Epoprostenol 
IV: 2 nanograms/kg per min; increase in increments of 2 nanograms/
kg per min at ≥ 15 minute intervals until response achieved or tole-
rance develops
Headache, jaw pain, flushing, GI upset, flu-like symptoms, anxiety, 
dizziness, tachycardia, myalgia
Iloprost
10 mcg/ml, 20 mcg/ml; soln for inhalation using I-neb six to nine 
times daily (no more than every 2 hours)
IV: 1 mg/ml for infusion
Vasodilation, increased cough, headache, lockjaw, insomnia, GI 
upset, hypotension, flu syndrome, back pain, increased GGT, alkaline 
phosphatase, tongue pain, palpitations, syncope, muscle cramps, 
hemoptysis, pneumonia, CHF, chest pain, supraventricular tachycar-
dia, dyspnea, peripheral edema, kidney failure
*All data was obtained from FDA Drug Information Data
of I-B has been given for both WHO FC II and III 
patients [3]. 
Another drug under investigation is Varde-
nafil, which is considered a PDE-5 inhibitor. It 
differs from already marketed PDE-5 inhibitors by 
having a short effective time and slight longer half 
life than that of sildenafil. The EVALUATION stu-
dy by Jing et al., which sought out to demonstrate 
safety and efficacy of Vardenafil showed that it is 
well tolerated in twice daily dosing and showed a 
increase in 6MWD, and cardiac index, along with 
an decrease in mean pulmonary arterial pressure 
and pulmonary vascular resistance [51]. Though 
not yet approved by the EMA based on the ERS 
guidelines a Class-Level recommendation of IIbB 
has been given for both WHO FC II and III patients 
and a recommendation of IIb-C for WHO FC IV 
patients [3].
In addition to traditional pathways a new 
class of drug exists. Bardoxolone methyl is an 
Nrf2 activator and NF-kB suppressor that targets 
dysfunctional inflammatory, metabolic, and 
bioenergetic pathways and is thought to have 
beneficial effects on endothelial dysfunction, 
as well as anti-proliferative and anti-fibrotic 
effects [52]. The LARIAT trail is a phase 2, 
dose-ranging, randomized, placebo-controlled, 
double-blind trial to assess exercise capacity and 
safety in patients taking stable PAH background 
therapy. Initial results showed bardoxolone 
methyl significantly increased placebo-correc-
ted 6MWD in PAH patients on background oral 
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PAH therapies and was well-tolerated at doses 
up to 10 mg [53].
There have also been exploratory studies 
into three pathways different than the ones men-
tioned above with unsatisfactory results using 
the following compounds: inhaled vasoactive 
intestinal peptide, tyrosine kinase inhibitors 
(platelet-derived growth factor inhibitors) and 
serotonin antagonists [3]. These drug compounds 
should be avoided.
Non pharmacological considerations
As there is presently no cure for PAH, in ad-
dition to these pharmaceutical options, supervi-
sed exercise training should be considered [54]. 
It has been shown to increase exercise capacity, 
WHO functional class, peak oxygen consumption 
and resting heart rate [55, 56]. It has also been 
observed that exercise may improve health rela-
ted quality of life (HRQoL) [30], depression and 
fatigue [57] which are all important in the overall 
well being of the patient. Nevertheless excessive 
physical activity leading to distressing symptoms 
is not recommended in PAH patients.
PAH specific therapy has reduced and de-
layed patient referral for lung transplant but it 
remains an important option for non-responders 
to therapy [58]. The outcome of medically treated 
patients is not always clear. Lung transplanta-
tion should continue to be an important option 
for those who fail on PAH specific therapy and 
remain in WHO-FC III or IV as it is for patients 
who have PHTN in the setting of interstitial lung 
disease [59]. 
Conclusion
Pulmonary arterial hypertension (PAH) is a 
rare and devastating disease due to direct inju-
ry to the pulmonary vessels and vascular bed. 
At present there is no cure for PAH, however 
targeted pharmaceutical options have become 
available for the treatment of PAH. There are 
different classes of medications available with 
different mechanisms of actions all which net a 
vasodilatory effect. After definitive diagnosis is 
made via right heart catheterization proper the-
rapeutic options should be explored depending 
on patients’ concurrent medication and medical 
conditions. 
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